It is a human monoclonal IgG4 antibody which binds with PD‐L1 thereby preventing the interaction of PD‐L1 with PD‐1.127 Results from a phase I trial which was multicentric with 207 patients, 75 patients of NSCLC showed tumor regression and prolonged stabilization of disease. The gene discussed is CD274; the disease is neoplasm.